When evaluating an AI visibility service for a pharma brand, check three things before you sign: pharma-industry grounding in the provider's methodology, buyer-journey-based question design rather than generic keyword lists, and measurement across all five major AI assistants (ChatGPT, Gemini, Perplexity, Claude, Grok). This article unpacks each criterion, names the warning signs of a generic agency, and gives you the questions to ask.
Disclosure: this article is published by AEO Dose, which provides AI visibility and AEO readiness audits for pharma businesses. The methodology described here reflects how AEO Dose approaches the work. The evaluation criteria apply to any provider in the category, including AEO Dose itself, and readers should hold any provider (us included) to them.
- Why knowing you need help is not the same as knowing how to vet it
- Why pharma AI visibility is a distinct discipline from consumer-brand work
- What a credible AI visibility audit actually measures
- Why a provider must test all five major AI assistants, not one or two
- The warning signs that a provider is a rebranded SEO shop
- How a provider should report findings and structure the engagement
- The questions to ask before you commit
The buyer's problem: knowing you need help is not the same as knowing how to vet it
Most pharma marketers evaluating this work are sophisticated enough to know they need it and not yet sophisticated enough to vet the people selling it. That gap is the real problem. You have read enough to understand that buyers now ask ChatGPT and Perplexity to shortlist suppliers, and that your brand either shows up in those answers or it does not. What you cannot easily judge is whether the provider in front of you actually knows how to move that outcome, or whether they have relabeled an SEO service and bolted the word "AI" onto the deck.
The AI visibility category is new enough that most providers come from SEO backgrounds, which is a 2024-2025 phenomenon. That is not a disqualification by itself. But it means the burden of proof sits with the provider to show their methodology was built for how AI assistants read and cite sources, not inherited from a decade of ranking blue links. AI Answer Engine Optimization is a distinct discipline, and if the category itself is unfamiliar, the Understanding AI Visibility and AEO cluster covers the fundamentals before you start comparing vendors.
Why pharma brands need different work than consumer brands
Pharma brands need different work because the buyers, the purchase logic, and the way different segments surface in AI answers are all different from consumer markets. A consumer brand wants to appear when someone asks for a moisturizer recommendation. A CDMO wants to appear when a formulation scientist asks which contract manufacturers handle high-potency solid dose at commercial scale. Those are not the same question, and a provider who treats them the same will misread what matters.
A credible provider should understand that an API manufacturer, an excipient supplier, a nutraceutical brand, and an oral care manufacturer each appear differently in AI answers, because the questions buyers ask about each segment are structured differently. The underlying signals (website structure, schema, third-party evidence) matter across all of them, but the questions that trigger a citation are segment-specific. The Industry-Specific Visibility Challenges cluster goes deeper into how CDMOs, excipient suppliers, and other segments show up differently. When you evaluate a provider, ask them to describe how your specific segment appears today. If they cannot, they are guessing.
What a credible audit actually measures
A credible audit measures how your brand actually appears when real buyers ask AI assistants the questions they would ask during a purchase, not how you rank for a keyword list. This is the distinction that separates genuine AI visibility work from repackaged SEO. The input is not keywords. The input is buyer-journey questions: the discovery, evaluation, capability, commercial, and support questions a real buyer moves through before they decide.
As a worked example of what this looks like in practice, AEO Dose structures its testing around five buyer-journey themes (discovery, evaluation, product and capability, commercial, and support) and runs the work through a defined cycle: Audit, Optimize, Build Authority, Measure, Repeat. The Free AI Visibility Check covers two platforms and ten real buyer questions; the Full Audit covers all five platforms across those five themes. The point is not that this is the only valid structure. The point is that a provider should be able to show you a defined methodology at all. The Audit and Optimization Process cluster documents how that cycle and buyer-journey question design work in detail. If a provider cannot articulate how they move from question to finding to recommendation, the deliverable will be a list of observations with no path to action.
Why multi-platform coverage is not optional
Multi-platform coverage matters because buyers do not standardize on one assistant, and the five major platforms return different answers to the same question. ChatGPT, Gemini, Perplexity, Claude, and Grok each weight sources differently, cite differently, and surface different suppliers. A provider who tests only one or two is reporting on a fraction of the surface where your buyers actually research.
This is where generic providers reveal themselves. In the absence of multi-platform testing, a provider can show you a clean result on a platform where you happen to perform well and quietly skip the ones where you are invisible. If your buyer uses Perplexity and the audit only covered ChatGPT, the finding is worthless to you. Ask the provider directly which platforms they test and ask to see raw results from each. The answer should be all five, with the outputs shown, not summarized into a single score.
The warning signs of a generic agency
A common warning sign is a proposal that leans on schema markup as the whole answer. Schema helps AI systems parse your pages, and it is worth doing. But the industry assumption that adding structured data alone moves AI citations does not hold up. Citations respond to a combination of signals: clear information structure, third-party evidence, entity consistency, and content that actually answers the buyer-journey questions. A provider who sells schema as the fix is selling the part that is easy to invoice, not the part that moves the outcome.
Other warning signs follow the same logic. Watch for keyword lists presented as the testing input, single-platform reporting dressed up as comprehensive, guaranteed rankings (no one can guarantee what a probabilistic model returns), and no pharma domain knowledge anywhere in the methodology. When a provider lacks pharma grounding, they cannot tell whether an AI answer about your capabilities is accurate, misleading, or damaging, because they do not know what good looks like in your segment. That is the difference domain experience makes. AEO Dose was founded by a B.Pharma graduate with more than twelve years in pharma ERP implementation and computer system validation, which shapes what gets tested and how findings get read. You should expect comparable grounding from whoever you hire.
How reporting and the engagement should look
Good reporting shows you the raw AI responses, the specific gaps, and a prioritized path to fix them, not a dashboard of invented scores. You should be able to read the actual answer each platform returned, see where your brand was absent or misrepresented, and understand which fixes come first and why. A finding without a recommendation is an observation, and observations do not change your visibility.
The engagement should not end at the audit. AI assistants update, competitors publish, and your own site changes, so a credible provider works in a cycle: audit, optimize, build authority, measure, then repeat. A one-time report is a snapshot of a moving surface. Ask what happens after the first deliverable and whether re-measurement is built in. On the operational side, small signals matter too: AEO Dose responds within one to two business days, and responsiveness during evaluation tends to predict responsiveness during the work.
The questions to ask before you sign
Ask these before you commit, this week, whether or not you are talking to us. First: which of the five platforms do you test, and can I see raw outputs from each? Second: how do you design the questions you test, and will you show me the buyer-journey questions specific to my segment? Third: what pharma experience sits inside your methodology? Fourth: beyond schema, what signals do you work on to move citations? Fifth: what does the engagement look like after the initial audit, and is re-measurement included?
A provider who answers these plainly, with examples, is worth continuing with. A provider who deflects to case studies without showing method is not. If you want a low-commitment way to test the criteria in this article against a real provider, run a free check and see the raw outputs for yourself: Get Your Free AI Visibility Check.



